Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia?
Pharmacopsychiatry
; 43(2): 73-80, 2010 Mar.
Article
em En
| MEDLINE
| ID: mdl-20131207
ABSTRACT
INTRODUCTION:
The objective of this open-label study was to evaluate treatment benefits of risperidone long-acting injectable (RLAI) in patients with schizophrenia following direct transition from oral risperidone (RIS) compared with transition from other oral second generation antipsychotics.METHODS:
Stable in- or outpatients (n=206) receiving RIS or OQAZ (olanzapine, quetiapine, amisulpride, ziprasidone) were transitioned to RLAI for 12 weeks. The primary outcome was the between-group treatment difference in change in PANSS total score from baseline to endpoint. Secondary outcomes included health-related quality-of-life and therapeutic alliance.RESULTS:
Mean between-group difference in the change in PANSS total score from baseline to endpoint was -6.1 (CI -17.6, 5.4), suggesting greater improvement in OQAZ than RIS patients. Due to the pre-specified non-inferiority margin of 5.1, it could not be concluded that OQAZ pre-treatment results in an at least non-inferior PANSS reduction versus RIS pre-treatment. Patient satisfaction with medication and change in quality-of-life subscores showed advantages for OQAZ patients.DISCUSSION:
Compared to RIS pre-treatment, clinically stable patients with schizophrenia who are pre-treated with OQAZ might draw a stronger clinical benefit from direct transition to RLAI.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Esquizofrenia
/
Antipsicóticos
/
Risperidona
Tipo de estudo:
Clinical_trials
/
Observational_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Pharmacopsychiatry
Ano de publicação:
2010
Tipo de documento:
Article
País de afiliação:
Alemanha